Medicine and technology can work together to produce amazing results. One of the most promising ‘marriages’ is that involving stem cell research and artificial intelligence (AI). Researchers are attempting to use AI to aid and augment stem cell technologies. How can machine learning play a role in restorative medicine? [Read more…]
What are the most promising drugs, antibodies, and vaccines in development against COVID-19? Our team sifted through hundreds of articles and research papers to identify the most promising ones. In most cases, these drugs, vaccines and antibodies are already in use for other diseases, making it easier to leverage them in the fight against the Coronavirus. [Read more…]
AlloVir’s proprietary technology is designed to develop virus specific T-cell therapies with potential to treat and prevent several devastating viral diseases with each single cell therapy product.
CAMBRIDGE, Mass & HOUSTON- AlloVir, a late-clinical stage T-cell immunotherapy company, today announced the expansion of its research and development collaboration with Baylor College of Medicine to include the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2, the virus that causes COVID-19. [Read more…]
Since the outbreak of the new type of coronavirus pneumonia (COVID-19) in December 2019, the scientific community has been working fervently to develop treatments to combat the disease. Globally, scientists are exploring every potential weapon to suppress the global threat. Approaches under investigation include vaccines, medications, combination therapies, and perhaps most interestingly, living therapies with promising cell types such as natural killer (NK) cells, stem cells and exosomes. [Read more…]
What is the Cymerus™ technology and how could it potentially assist in the war against Coronavirus cases on a global basis? Cymerus™ is a stem cell manufacturing platform being developed by Cynata Therapeutics Limited (ASX: CYP), an Australian regenerative medicine company.
The proprietary technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating mesenchymoangioblasts (MCAs). It then differentiates these cells into mesenchymal stem cells (MSCs). [Read more…]